TargetMol

RO6889678

Product Code:
 
TAR-T9054
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T9054-1mg1mg£125.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9054-2mg2mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9054-5mg5mg£181.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9054-1mL1 mL * 10 mM (in DMSO)£206.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9054-10mg10mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9054-25mg25mg£298.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9054-50mg50mg£434.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9054-100mg100mg£605.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
RO6889678 is HBV inhibitor with a complex ADME profile.
CAS:
1578153-27-1
Formula:
C21H20ClFN4O5S
Molecular Weight:
494.92
Pathway:
Microbiology/Virology
Purity:
0.9872
SMILES:
COC(=O)C1=C(CN2CCOC[C@H]2C(O)=O)NC(=N[C@H]1c1ccc(F)cc1Cl)c1nccs1
Target:
HBV

References

Kratochwil N A , Triyatni M , Mueller M B , et al. Simultaneous Assessment of Clearance, Metabolism, Induction and Drug-Drug Interaction Potential using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor[J]. Journal of Pharmacology & Experimental Therapeutics, 2018:jpet.117.245712.